Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer’s and other Dementia Diseases

Posted In: Company News

Metabolon collaboration will combine metabolomics with neurological and clinical phenotyping to develop new biomarkers.

MORRISVILLE, N.C. – September 13, 2022 – Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with the Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) 2 Study. The partnership aims to develop novel metabolomic biomarkers, assist in the development of new pathology-based disease classifications, and investigate underlying disease mechanisms of dementia to help discover new relevant drug targets.

Despite massive research and drug development, there are still limited to no therapies that slow down or stop the progression of dementia and Parkinsonian diseases. The Swedish BioFINDER 2 Study brings together leading scientists, universities, and companies worldwide and is designed to address issues related to the role of tau pathology in a broad spectrum of neurological diseases.

As part of the partnership, Metabolon will run metabolomics on both cerebrospinal fluid (CSF) and plasma from BioFINDER 2’s baseline collections. By combining metabolomics with comprehensive neurological and clinical phenotyping, Metabolon will identify metabolomic biomarkers to monitor the early effects of new disease-modifying therapies and provide methods for early and accurate diagnosis of different dementia disorders. Metabolon and the Swedish BioFINDER 2 Study will also define the temporal evolution of pathologies in the pre-dementia phases of Alzheimer’s. Additionally, metabolomics will be integrated with GWAS to further understand these neurological diseases.

“We are excited to collaborate with BioFINDER 2 to support early dementia disease research,” said Ro Hastie, President & CEO of Metabolon. “Adding metabolomics to this already successful study will allow our researchers to reveal new biomarkers to support a greater understanding of dementia diseases and better inform successful drug development.”

To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/.

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos
Germany

+49 89 99017752